Curated news and analysis on clinical trials, drug approvals, and medical research.
The FDA issued reforms on January 11, 2026, loosening chemistry, manufacturing, and control requirements for cell and gene therapy products to advance innovation and accommodate the unique complexity of these treatments.
The global next generation drug conjugates market is projected to grow from $3.9 billion in 2026 to $10.9 billion by 2033 at 15.3% CAGR, while the radionuclide drug conjugate segment is forecast to reach $20.22 billion by 2032 at 9.6% CAGR.
Exploratory analysis from a phase 1/2 trial shows CD47 expression levels predict response to evorpacept plus zanidatamab in heavily pretreated HER2-positive metastatic breast cancer patients, supporting biomarker-driven patient selection.
The FDA has approved leucovorin for cerebral folate deficiency with FOLR1 gene variant, not for autism broadly. Agency officials cited insufficient data for broader autism efficacy despite previous hype. Prescriptions for the drug surged 71% among children following earlier promotional statements.
Sagimet Biosciences reported fourth quarter and full year 2025 financial results, announcing plans to initiate a Phase 2 trial of denifanstat and resmetirom combination in F4 MASH patients in the second half of 2026, with a 26-week biomarker readout expected in the first half of 2028.
Ascletis Pharma announced positive Phase II results for subcutaneous ASC30 showing 6.3% placebo-adjusted weight loss at 12 weeks, while advancing oral amylin receptor agonist ASC36 toward US FDA IND submission for obesity treatment.
The FDA has granted fast track designation to QRX003 for Netherton Syndrome and IBI3003 for relapsed or refractory multiple myeloma, while also accepting regulatory applications for other therapies addressing serious conditions with unmet medical needs.
Researchers have created a nasal vaccine platform that protects mice against flu, COVID-19, SARS, and bacterial infections by activating both innate and adaptive immune systems, offering a fundamentally different approach to disease prevention.
Researchers at the Regina Elena National Cancer Institute in Rome discovered how the hMENA protein enables non-small cell lung cancer to resist immunotherapy by regulating cancer-associated fibroblasts that create a protective tumor microenvironment.
Recent studies demonstrate zanubrutinib delivers higher response rates, longer treatment persistence, and lower healthcare costs compared to acalabrutinib and ibrutinib across multiple B-cell malignancies, with particularly strong benefits in high-risk populations.
The Consolidated Appropriations Act, 2026 enacted February 3 narrows orphan drug exclusivity to specific approved uses rather than entire disease categories, overriding a 2021 court decision and codifying FDA's longstanding interpretation.
The Mississippi Department of Environmental Quality issued an air permit to xAI for 41 gas turbines to power its Colossus II data center, despite a lawsuit threat from the NAACP alleging Clean Air Act violations and community concerns about air quality impacts.
New technologies combining patient-derived organoid models with artificial intelligence are enabling researchers to predict treatment responses and monitor tumor behavior in ways that could advance personalized cancer care.
The FDA has established a "plausible mechanism pathway" to approve personalized genome editing and RNA-based therapies for rare and ultra-rare diseases without requiring large randomized controlled trials, streamlining access to individualized treatments.
Recent studies demonstrate PD-1 antibody combinations improve survival in natural killer/T-cell lymphoma and show activity in previously treated advanced non-small cell lung cancer, with manageable safety profiles across treatment settings.
The FDA is expected to issue draft guidance reducing testing requirements for biosimilar drugs, potentially lowering development costs by USD 20 million. The move comes as the biosimilars market shows strong growth, with major launches in 2025.
IDEAYA Biosciences announced Q4 2025 financial results with $1.05 billion in cash reserves and confirmed 130 progression-free survival events in its Phase 2/3 OptimUM-02 trial of darovasertib for metastatic uveal melanoma, with topline results expected by late March 2026.
AstraZeneca terminated its Phase I/IIa trial of AZD0022 for KRASG12D-mutant cancers, withdrew a planned saruparib ovarian cancer platform study, and completed a real-world non-small cell lung cancer treatment review.
LIXTE Biotechnology Holdings appointed Sidney Braun as CEO of its Liora Technologies Europe Ltd. subsidiary to lead advancement of the LiGHT System proton therapy platform following the company's November 2025 acquisition of Liora's assets.
Researchers at Duke University discovered that specialized immune cells called resident macrophages maintain the eye's drainage system and regulate pressure, potentially providing a new therapeutic target for glaucoma treatment beyond current symptom management approaches.
